Refsum's Disease-Use of the Intestinal Lipase Inhibitor, Orlistat, as a Novel Therapeutic Approach to a Complex Disorder
Refsum's Disease is an inherited metabolic disorder in which a metabolite of branched chain fatty acids accumulates due to lack of appropriate oxidative enzymes. Patients have elevated plasma phytanic acid levels and high concentrations of phytanic acid in a variety of tissues leading to progre...
Saved in:
Main Authors: | Nimalie J. Perera (Author), Barry Lewis (Author), Huy Tran (Author), Michael Fietz (Author), David R. Sullivan (Author) |
---|---|
Format: | Book |
Published: |
Hindawi Limited,
2011-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Infantile Refsum Disease
by: J Gordon Millichap
Published: (1988) -
Caso clínico: tratamiento nutricional de un desorden genético llamado Síndrome de Refsum
by: Ángela del Socorro Franco Castro
Published: (2009) -
Acute oxalate nephropathy associated with orlistat
by: Youshay Humayun, et al.
Published: (2016) -
Development and validation by statistical treatment of stability indicating RP-HPLC method for quantification of Orlistat in Orlistat-loaded solid dispersion
by: Kiran Singh Sharma, et al.
Published: (2021) -
Monoacylglycerol lipase inhibitors: modulators for lipid metabolism in cancer malignancy, neurological and metabolic disorders
by: Hui Deng, et al.
Published: (2020)